RH-ENDOSTATIN PLUS GEMCITABINE/NAVELBINE AND CISPLATIN AS FIRST-LINE TREATMENT PROTOCOL FOR NON-SMALL CELL LUNG CANCER PATIENTS:A SINGLE CENTRE STUDY  

作　　者：周剑平 项轶 万欢英 高蓓莉 

机构地区：[1]Department of Respiratory Medicine,Ruijin Hospital,Shanghai Jiaotong University School of Medicine

出　　处：《Medical Bulletin of Shanghai Jiaotong University》2011年第1期32-37,共6页上海交通大学学报（医学英文版）

摘　　要：Objective To assess the efficacy of Rh-endostatin plus the combination of gemcitabine/navelbine and cisplatin in patients with non-small cell lung cancer (NSCLC).Methods NSCLC patients,not receiving chemotherapy,were divided into two groups.Then they were given the combination of gemcitabine/navelbine and cisplatin with or without Rh-endostatin at 2-week intervals for 4 treatment cycles.Results Forty patients were enrolled and all of them were assessable for response and toxicity.None had complete response but 4 patients had partial response.An overall response rate was 10%.The survival rate was 65% at 1 year,with a median survival time of 16.2 months.Hematological complications were the most common toxic reactions,with grade≥3 reactions occurring at rates of 7%,7%,4% and 2%,respectively.Conclusion Rh-endostatin may have anti-tumor activity with high clinical benefit rate and is well tolerated in lung cancer with stage Ⅲb/Ⅳ.Compared with single combination of gemcitabine/navelbine and cisplatin,no more significant unexpected adverse events were observed.Objective To assess the efficacy of Rh-endostatin plus the combination of gemcitabine/navelbine and cisplatin in patients with non-small cell lung cancer (NSCLC). Methods NSCLC patients, not receiving chemotherapy, were divided into two groups. Then they were given the combination of gemcitabine/navelbine and cisplatin with or without Rh-endostatin at 2-week intervals for 4 treatment cycles.Results Forty patients were enrolled and all of them were assessable for response and toxicity. None had complete response but 4 patients had partial response. An overall response rate was 10％. The survival rate was 65％ at 1 year, with a median survival time of16. 2 months. Hematological complications were the most common toxic reactions, with grade≥ 3 reactions occurring at rates of 7％, 7％ , 4％ and 2％ , respectively.Conclusion Rh-endostatin may have anti-tumor activity with high clinical benefit rate and is well tolerated in lung cancer with stage Ⅲb/Ⅳ. Compared with single combination of gemcitabine/navelbine and cisplatin, no more significant unexpected adverse events were observed.

关 键 词：non-small cell lung cancer Rh-endostatin efficacy toxicity 

分 类 号：R734[医药卫生—肿瘤]